Peptide Comparison
Substance P AntagonistsvsTB-500
NK1 receptor blockers that reduce pain signals and nausea at the source
A powerful fragment of thymosin beta-4 that acts like your body's repair signal—speeding up healing of muscles, tendons, and tissues by promoting cell migration and new blood vessel growth right where you need it most.
At a Glance
Quick
comparison
Dose Range
Substance P Antagonists
80 mg–125 mg mg
TB-500
2–5 mg
Frequency
Substance P Antagonists
Once daily
TB-500
Twice weekly
Administration
Substance P Antagonists
Oral capsule
TB-500
Subcutaneous injection
Cycle Length
Substance P Antagonists
Ongoing/indefinite
TB-500
4-6 weeks
Onset Speed
Substance P Antagonists
Moderate (1-2 weeks)
TB-500
Moderate (1-2 weeks)
Evidence Level
Substance P Antagonists
Moderate human trials (Phase 1-2)
TB-500
Moderate human trials (Phase 1-2)
Efficacy
Benefit
ratings
Anti-Nausea & Antiemetic
Pain Modulation
Neuroprotection
Healing Speed
Tissue Repair
Anti-Scarring
Technical Data
Compound
specifications
Substance P Antagonists
Molecular Formula
C23H21F7N4O3
Molecular Weight
534.4 g/mol
Half-Life
9-13 hours (elimination half-life)
Bioavailability
Approximately 60-65% oral bioavailability; food may increase absorption
CAS Number
170729-80-3
TB-500
Molecular Formula
C38H68N10O14
Molecular Weight
889.01 g/mol
Half-Life
2-3 days (systemic)
Bioavailability
High via subcutaneous injection (~100%)
CAS Number
885340-08-9
Protocols
Dosing
tiers
Substance P Antagonists
TB-500
Applications
Best
suited for
Substance P Antagonists
Managing severe nausea from cancer treatments
Substance P Antagonists is particularly well-suited for individuals focused on managing severe nausea from cancer treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Chronic pain reduction
Substance P Antagonists is particularly well-suited for individuals focused on chronic pain reduction. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving quality of life during intensive medical therapy
Substance P Antagonists is particularly well-suited for individuals focused on improving quality of life during intensive medical therapy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
TB-500
Athletes Recovering from Muscle Injuries
If you've pulled a hamstring, strained your back, or torn a muscle, TB-500 helps accelerate the healing process by promoting cell migration to the injury site and supporting new blood vessel growth. It's especially useful for injuries that just won't seem to fully heal.
Tendon and Ligament Problems
Tendons and ligaments are notoriously slow healers because they have poor blood supply. TB-500 promotes angiogenesis (new blood vessel formation) and helps repair these stubborn connective tissue injuries—think Achilles tendonitis, tennis elbow, or rotator cuff issues.
Post-Surgical Recovery
After surgery, your body needs to repair a lot of tissue quickly. TB-500 supports wound healing, reduces inflammation, and may help minimize scar tissue formation. Some protocols use it alongside traditional recovery to potentially speed up the healing timeline.
Chronic Inflammation and Slow Healers
Some people just heal slowly—whether due to age, diabetes, or other factors. TB-500 helps regulate the inflammatory response and promotes the cellular processes needed for tissue repair. It essentially tells your body to focus healing resources where they're needed most.
Safety Profile
Side
effects
Substance P Antagonists
Common
- Headache
- Fatigue or weakness
- Constipation
Uncommon
- Loss of appetite
- Dizziness
Serious
- Stevens-Johnson Syndrome (SJS)
TB-500
Common
- Injection site redness
- Mild fatigue or lethargy
- Mild headache
- Slight flushing
Uncommon
- Head rush or lightheadedness
- Temporary nausea
Serious
- Allergic reaction
Research Status
Safety
& evidence
Substance P Antagonists
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
FDA approved for this use
Safety Overview
Aprepitant (the primary NK1 antagonist) has been FDA-approved since 2003 with extensive safety data in over 50,000 cancer patients receiving highly emetogenic chemotherapy. Most common adverse events are mild to moderate—headache (15-20%), fatigue, and constipation—which are often difficult to attribute solely to aprepitant versus underlying malignancy or chemotherapy effects. Serious but rare adverse events include Stevens-Johnson syndrome (extremely uncommon) and QT prolongation (in susceptible individuals), requiring baseline ECG evaluation in high-risk patients.
Contraindications
- xSevere hypersensitivity to aprepitant or any component
- xConcurrent use with certain other medications that affect the liver
- xSevere cardiac conditions
TB-500
Evidence Level
Moderate human trials (Phase 1-2)
FDA Status
Research compound
Safety Overview
TB-500 has shown a good safety profile across preclinical studies and limited human research. It's a fragment of thymosin beta-4, a naturally occurring protein in your body involved in healing. Most side effects are mild and transient, primarily injection site reactions. However, large-scale clinical trials are still needed to fully establish its safety profile in humans.
Contraindications
- xPregnancy or planning to become pregnant
- xCurrently breastfeeding
- xActive cancer or history of cancer
- xKnown allergy to peptide components
- xChildren and adolescents
Decision Guide
Which is
right for you?
Choose Substance P Antagonists if...
- Managing severe nausea from cancer treatments
- Chronic pain reduction
- Improving quality of life during intensive medical therapy
Choose TB-500 if...
- Accelerating injury recovery
- Tendon and ligament healing
- Reducing chronic inflammation
- Post-surgical recovery support